Rationale for the GEMSTONE-302 Study in Lung Cancer
Jamie E. Chaft, MD, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer.
Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC).
Multiple studies have shown that the combination of chemotherapy and immunotherapy is better than chemotherapy and placebo, says Chaft. Research has also shown that chemotherapy plus immunotherapy is comparable to immunotherapy alone in patients with tumors that highly expressed PD-L1.
The GEMSTONE-302 is another example of these prior studies but focuses on patients in China. Chaft explains that positive results would not be surprising to see and there is hope that the treatment strategy will allow an additional therapeutic option for patients with advanced NSCLC.
